Application of protein C in treating hepatic portal hypertension

A technique of arterial hypertension and hepatic portal, applied in the application field of protein C in the treatment of hepatic portal hypertension-related diseases, can solve the problems of lack of research on the pathogenesis and treatment mechanism of portal hypertension, and achieve tissue reduction and lower portal hypertension. Pulse pressure, the effect of promoting apoptosis

Active Publication Date: 2019-08-23
首都儿科研究所
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Overall, there is still a lack of in-depth research on t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of protein C in treating hepatic portal hypertension
  • Application of protein C in treating hepatic portal hypertension
  • Application of protein C in treating hepatic portal hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1. Detection of relative content of activated protein C (PROTEIN C, PROC).

[0032] 1. Experimental group

[0033] Control group: whole blood samples from 6 normal children

[0034] Experimental group: Whole blood samples from 6 children with low protein C levels after portal vein cavernous degeneration Rex operation

[0035] 2. ELISA experiment

[0036] Set blank wells, standard wells and sample wells to be tested respectively. Blank wells (do not add samples, enzyme-labeled reagents and biotin-labeled anti-PROTEIN C antibodies, and the rest of the steps are the same), add 50 μL of standard products to the standard wells, add 400 μL of the sample to be tested, and then add biotin-labeled Anti-MCP3 antibody 10μL, shake gently to mix. The experimental steps were carried out according to the ELISA experimental operating procedures. The optical density (OD value) of each well was measured with a microplate reader at a wavelength of 450 nm.

[0037] 3. Experim...

Embodiment 2

[0039] Embodiment 2, detect the relative content of miRNA and PROC mRNA

[0040] 1. Primer design

[0041] Table 1 Primer Sequence

[0042]

[0043]

[0044] 2. Extraction of RNA

[0045]1. Use TRI REAGENT BD kit to extract RNA in plasma, add 0.25mL plasma and 1-4μL polyacrylamide carrier to TRI reagent, mix thoroughly and place at room temperature for 5min.

[0046] 2. Add 0.2mL chloroform or 0.1mL BCP to each TRI reagent, shake well for 15s, let stand at room temperature for 2-5min, centrifuge at 12000g for 15min at 4°C, and absorb the upper aqueous phase.

[0047] 3. Add 0.5mL isopropanol to each TRI reagent and mix well, place at room temperature for 5-10min, centrifuge at 12000g for 10min at 4°C, discard the supernatant, and the RNA will sink to the bottom of the tube.

[0048] 4. Add 1mL of 75% ethanol to each TRI reagent, shake the centrifuge tube, suspend the precipitate, centrifuge at 7500g at 4°C for 5min, discard the supernatant, and dry at room temperature...

Embodiment 3

[0076] Embodiment 3, verify the double luciferase experiment of PROC target gene

[0077] 1. Experimental group

[0078] (1) NC mimics+Luc-PROCwt. (2) miR-506mimic+Luc-PROCwt. (3) miR-124mimic+Luc-PROCwt. (4) NC mimics+Luc-PROCmut. (5) miR-506mimic+Luc-PROCmut. (6) miR-124mimic+Luc-PROCmut.

[0079] After miRNA mimics, firefly luciferase and Renilla luciferase plasmids were co-transfected into 293T cells for 48 hours, Luciferase activity was detected.

[0080] 2. Experimental steps

[0081] 1. Discard the medium, wash with 1x PBS, and discard the PBS.

[0082] 2. Add 100 μL 1x PLB (1 volume of 5X Passive Lysis Buffer plus 4 volumes of double-distilled water) to each well, and place on a shaker at room temperature for 15 minutes.

[0083] 3. After the cells are fully lysed, add the lysate to the 96-well plate, and add 20 μL to each sample.

[0084] 4. Add 100 μL LAR II to each well of the sample to be tested (use Luciferase Assay Buffer II to resuspend Luciferase Assay...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of protein C in treating hepatic portal hypertension, relates to the relevant research of the protein C and portal hypertension, and also relates to protein C inhibitors including miRNA. The protein C inhibitor (miRNA) can inhibit the proliferation of hepatocytes and promote the apoptosis of the hepatocytes, which can reduce hyperplasia tissue of hepatic sinusoids to make portal venous flow smooth and reduce the portal pressure, thereby opening up new research prospects for the treatment of the portal hypertension (especially portal vein cavernous transformation) and providing new ideas for the deep development of miRNA drugs and clinical treatment.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of protein C in the treatment of diseases related to hepatic portal hypertension. Background technique [0002] Portal hypertension (PH), also known as portal hypertension, portal hypertension, and portal hypertension, is defined as portal hypertension (PH) when the portal pressure increases more than 5 mmHg relative to systemic blood pressure. The basic pathological and physiological characteristics of PH are obstruction and / or increased blood flow in the portal vein system, continuous increase in hydrostatic pressure in the portal vein and its branches, and the formation of collateral circulation. Cirrhosis of the liver due to various causes is its most common cause. The main clinical manifestations are gastroesophageal varices (GOV), esophagogastric variceal bleeding (EVB), ascites, and hepatic encephalopathy, among which EVB is the most lethal complication of PH, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/113C12N15/63A61K31/7105A61P9/12
CPCA61K31/7105A61P9/12C12N15/113
Inventor 张金山
Owner 首都儿科研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap